Orris

Proteomics in cancer Robbins based md pathology exams answer

Reading File
Finding Sources
Finding Sources
Searching PubMed

cancer proteomics

Searching the Web

cancer proteomics biomarkers clinical applications review 2025

Finding Sources
Finding Sources
Reading File
Reading File

Proteomics in Cancer

Proteomics is the large-scale study of the entire protein complement (proteome) of a cell, tissue, or body fluid, including protein quantity, structure, interactions, and post-translational modifications. In cancer, it complements genomic and transcriptomic analysis by showing the functional protein changes that actually drive tumor behavior.

Principle

A cancer cell may contain DNA mutations and altered RNA expression, but proteins are the final effectors of cell proliferation, apoptosis resistance, invasion, angiogenesis, and immune evasion. Proteomic analysis measures many proteins simultaneously to identify tumor-specific protein-expression patterns.
Robbins places proteomics among molecular profiling methods that assess the genome, epigenome, transcriptome, proteome, and metabolome. Robbins & Kumar Basic Pathology, p. 258.

Techniques

  • Mass spectrometry (MS): Main method for identifying and quantifying proteins and peptides.
  • Two-dimensional gel electrophoresis: Separates proteins based on isoelectric point and molecular weight.
  • Protein microarrays: Detect multiple proteins, antibodies, or protein interactions simultaneously.
  • Immunohistochemistry (IHC): Localizes and semiquantifies specific proteins in tissue sections.
  • Reverse-phase protein arrays: Useful for measuring signaling-pathway proteins and phosphorylated proteins.

Applications in Cancer

  1. Biomarker discovery
    • Detection of proteins in tumor tissue, serum, plasma, urine, or other body fluids.
    • Potential uses include early detection, diagnosis, prognosis, prediction of response, and surveillance for recurrence.
    • Examples of clinically established protein biomarkers include PSA in prostate cancer, HER2 in breast/gastric cancer, and CA-125 in ovarian cancer, though these are not all products of modern discovery proteomics.
  2. Tumor classification
    • Protein-expression signatures may help distinguish tumors with similar morphology but different molecular pathways or prognosis.
  3. Prognostic assessment
    • Identifies proteins associated with aggressive behavior, metastasis, angiogenesis, treatment resistance, or likelihood of recurrence.
  4. Predicting treatment response
    • Proteins can serve as therapeutic targets or predictive biomarkers.
    • Example: HER2 protein overexpression/amplification identifies patients who may benefit from anti-HER2 therapy.
    • Analysis of phosphoproteins may indicate activation of signaling pathways such as EGFR, PI3K-AKT, or MAPK.
  5. Drug-target discovery
    • Can identify overexpressed oncoproteins, abnormal signaling pathways, protein interactions, and post-translational modifications that may be therapeutically targetable.
  6. Understanding tumor heterogeneity and microenvironment
    • Proteomics may study cancer cells, stroma, immune cells, extracellular matrix, and tumor-secreted proteins.
    • Spatial proteomics can relate protein expression to histologic location within the tumor.

Advantages

  • Measures the functional products of genes directly.
  • Detects post-translational modifications, especially phosphorylation, glycosylation, and acetylation, which genomic tests may not reveal.
  • May identify druggable targets and predictive biomarkers.
  • Can be applied to tumor tissue and potentially to body fluids for minimally invasive testing.

Limitations

  • Proteins are highly variable and influenced by tissue handling, ischemia time, degradation, inflammation, and treatment.
  • The proteome is dynamic, complex, and has a very wide concentration range.
  • Low-abundance tumor proteins are difficult to detect in blood.
  • Discovery findings need rigorous analytical and clinical validation.
  • A protein marker may lack sufficient sensitivity or specificity for screening.
  • Proteomic and epigenomic approaches remain mainly research tools in routine cancer practice, whereas DNA-based molecular testing is more established. Robbins & Kumar Basic Pathology, p. 259.

Short conclusion

Proteomics studies global protein expression and modification in cancer. It has major potential for discovering biomarkers, defining activated pathways, predicting prognosis and therapy response, and identifying new drug targets. However, due to technical variability and the need for validation, its routine clinical use is still more limited than genomic testing.
Exam line:
Proteomics is the large-scale analysis of proteins expressed by tumor cells. It provides functional information beyond genomic analysis and may aid in biomarker discovery, prognosis, therapeutic prediction, and identification of molecular targets, but currently remains largely a research-based approach.
Recent systematic reviews continue to support biomarker-discovery potential but also reflect the need for validation before broad clinical implementation, including a 2025 breast-cancer proteomics review (PMID: 40953753).

Make a one-page PDF revision note on cancer proteomics

Reading File
Reading File
Finding Sources
Searching PubMed

cancer proteomics

Searching the Web

NCI proteomics cancer biomarkers proteomics

Browsing Directory

~/

Running Command

mkdir -p "/tmp/workspace/cancer-proteomics-revision/src" "/tmp/workspace/cancer-proteomics-revision/output" && python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.lib.units import mm from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, KeepTogether from reportlab.pdfbase.ttfonts import TTFont from reportlab.pdfbase import pdfmetrics from reportlab.pdfbase.pdfmetrics import stringWidth out='/tmp/workspace/cancer-proteomics-revision/output/Cancer_Proteomics_Robbins_Revision_Note.pdf' page_w,page_h=A4 margin=11*mm def P(text, style): return Paragraph(text, style) styles=getSampleStyleSheet() base=ParagraphStyle('base', parent=styles['BodyText'], fontName='Helvetica', fontSize=8.15, leading=9.65, textColor=colors.HexColor('#172033'), spaceAfter=0) small=ParagraphStyle('small', parent=base, fontSize=7.0, leading=8.2, textColor=colors.HexColor('#42536B')) title=ParagraphStyle('title', parent=styles['Title'], fontName='Helvetica-Bold', fontSize=22, leading=23, alignment=TA_CENTER, textColor=colors.HexColor('#083B66'), spaceAfter=2) sub=ParagraphStyle('sub', parent=base, alignment=TA_CENTER, fontSize=8.2, leading=10, textColor=colors.HexColor('#45647E'), spaceAfter=5) head=ParagraphStyle('head', parent=base, fontName='Helvetica-Bold', fontSize=9.3, leading=11.2, textColor=colors.white, spaceAfter=0) section=ParagraphStyle('section', parent=base, fontName='Helvetica-Bold', fontSize=9.4, leading=11.2, textColor=colors.HexColor('#083B66'), spaceAfter=2) key=ParagraphStyle('key', parent=base, fontName='Helvetica-Bold', textColor=colors.HexColor('#083B66')) box=ParagraphStyle('box', parent=base, fontSize=8.3, leading=10.0) story=[] story += [P('CANCER PROTEOMICS', title), P('Robbins-based pathology revision note | Molecular profiling of tumours', sub)] # Definition callout callout=Table([[P('<b>ONE-LINE DEFINITION</b><br/>Proteomics is large-scale analysis of the <b>proteome</b>: the proteins expressed by tumour cells or biofluids, including their abundance, modifications and interactions. It reveals the functional output of cancer genomes.', box)]], colWidths=[188*mm]) callout.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),colors.HexColor('#E8F4FB')),('BOX',(0,0),(-1,-1),0.7,colors.HexColor('#5AA6C8')),('LEFTPADDING',(0,0),(-1,-1),7),('RIGHTPADDING',(0,0),(-1,-1),7),('TOPPADDING',(0,0),(-1,-1),5),('BOTTOMPADDING',(0,0),(-1,-1),5)])) story += [callout, Spacer(1,5)] left=[] left += [P('1. WHERE IT FITS IN ROBBINS', section), P('<b>Molecular profiling</b> evaluates: <b>genome</b> (DNA sequence), <b>epigenome</b>, <b>transcriptome</b> (RNAs), <b>proteome</b> (many proteins simultaneously), and <b>metabolome</b>.', base), Spacer(1,3), P('Why protein level matters', section), P('DNA/RNA abnormalities do not always predict protein abundance or activity. Proteomics can identify the actual molecules executing tumour-cell functions and detect <b>post-translational modifications</b>, especially phosphorylation, that signal pathway activation.', base), Spacer(1,4), P('2. METHODS TO REMEMBER', section)] methods=[['Method','Exam point'],['Mass spectrometry','Identification and quantification of proteins/peptides; core discovery platform.'],['Protein microarrays / reverse-phase arrays','Parallel measurement of proteins and signaling-pathway proteins; useful for phosphorylated proteins.'],['IHC','Localises a specific protein in tumour sections; preserves tissue architecture.'],['2-D gel electrophoresis','Older separation method by charge and molecular mass.']] t=Table([[P(f'<b>{r[0]}</b>',small) if i else P(f'<b>{r[0]}</b>',small),P(r[1],small) if i else P(f'<b>{r[1]}</b>',small)] for i,r in enumerate(methods)],colWidths=[48*mm,43*mm]) t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),colors.HexColor('#D7EAF5')),('GRID',(0,0),(-1,-1),0.35,colors.HexColor('#AAC9D9')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),4),('RIGHTPADDING',(0,0),(-1,-1),4),('TOPPADDING',(0,0),(-1,-1),3),('BOTTOMPADDING',(0,0),(-1,-1),3)])) left += [t,Spacer(1,4),P('3. WHAT IT CAN DO',section), P('<b>Biomarkers:</b> discover candidates in tumour, serum/plasma, urine and other fluids for diagnosis, prognosis, therapy prediction and recurrence monitoring.',base),Spacer(1,2), P('<b>Biology:</b> define active signaling networks, tumour heterogeneity, microenvironment and mechanisms of invasion or resistance.',base)] right=[] right += [P('4. CLINICAL APPLICATIONS',section), P('<b>Classification:</b> protein-expression signatures may separate biologically distinct tumour subsets.',base),Spacer(1,2), P('<b>Prognosis:</b> identify proteins linked to aggressive behaviour, metastasis or recurrence.',base),Spacer(1,2), P('<b>Predictive biomarkers and targets:</b> show whether a target protein/pathway is present or activated. Example: <b>HER2</b> overexpression/amplification supports anti-HER2 therapy selection.',base),Spacer(1,2), P('<b>Proteogenomics:</b> integrates proteomic data with genomic and transcriptomic changes, linking mutations to downstream functional proteins and possible drug targets.',base),Spacer(1,4), P('5. LIMITATIONS - HIGH-YIELD',section), P('• Proteome is dynamic and varies with tissue handling, ischemia, inflammation and treatment.<br/>• Wide range of protein concentrations makes low-abundance proteins hard to detect, especially in blood.<br/>• Discovery signals require strict analytical and clinical validation for sensitivity, specificity and reproducibility.<br/>• Tumour heterogeneity can cause sampling bias.',base),Spacer(1,4), P('ROB BINS TAKE-HOME',section)] take=Table([[P('<b>Current status:</b> In Robbins, proteomics and epigenomics are used mainly in <b>clinical research</b>; DNA-based molecular testing is more established in routine care. Histopathology remains indispensable because it reveals anaplasia, invasion, tumour heterogeneity and tumour-stromal/immune relationships that sequence data alone cannot provide.',box)]],colWidths=[91*mm]) take.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),colors.HexColor('#FFF3D6')),('BOX',(0,0),(-1,-1),0.7,colors.HexColor('#D6A33D')),('LEFTPADDING',(0,0),(-1,-1),6),('RIGHTPADDING',(0,0),(-1,-1),6),('TOPPADDING',(0,0),(-1,-1),5),('BOTTOMPADDING',(0,0),(-1,-1),5)])) right += [take,Spacer(1,4),P('<b>EXAM ANSWER:</b> “Cancer proteomics is large-scale study of tumour proteins. It complements genomics by identifying functional protein expression and post-translational changes, with potential roles in biomarker discovery, prognosis, prediction of therapy response and target identification. Its routine clinical application remains limited by technical variability and the need for validation.”',box)] cols=Table([[left,right]],colWidths=[92*mm,92*mm]) cols.setStyle(TableStyle([('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),0),('RIGHTPADDING',(0,0),(-1,-1),0),('LINEAFTER',(0,0),(0,0),0.5,colors.HexColor('#B8CEDB')),('LEFTPADDING',(1,0),(1,0),7)])) story += [cols,Spacer(1,5)] footer=Table([[P('Source: Robbins & Kumar Basic Pathology, “Molecular Profiling of Tumors,” pp. 258-259. Updated context: NCI describes proteomics/proteogenomics as avenues for tumour-marker discovery; translation requires validation.',small)]],colWidths=[188*mm]) footer.setStyle(TableStyle([('LINEABOVE',(0,0),(-1,0),0.35,colors.HexColor('#9EB7C7')),('TOPPADDING',(0,0),(-1,-1),4),('LEFTPADDING',(0,0),(-1,-1),0),('RIGHTPADDING',(0,0),(-1,-1),0)])) story += [footer] doc=SimpleDocTemplate(out,pagesize=A4,rightMargin=margin,leftMargin=margin,topMargin=9*mm,bottomMargin=9*mm,title='Cancer Proteomics - Robbins Revision Note',author='Orris') doc.build(story) print(out) PY

Running Command

python - <<'PY' from pypdf import PdfReader p='/tmp/workspace/cancer-proteomics-revision/output/Cancer_Proteomics_Robbins_Revision_Note.pdf' r=PdfReader(p) print('pages=',len(r.pages)) text=r.pages[0].extract_text() print('chars=',len(text)) print(text[:600]) PY ls -lh "/tmp/workspace/cancer-proteomics-revision/output/Cancer_Proteomics_Robbins_Revision_Note.pdf"

One-page PDF revision note, verified as a single page:

Cancer Proteomics Robbins Revision Note

PDF Document · PDF

This is a shared conversation. Sign in to Orris to start your own chat.